Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,14643505,absolute recovery,The mean absolute recovery for human plasma was 93.5 +/- 4.2% for triflusal and 98.5 +/- 3.1% for HTB.,"Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643505/),%,93.5,20535,DB08814,Triflusal
,14643505,absolute recovery,The mean absolute recovery for human plasma was 93.5 +/- 4.2% for triflusal and 98.5 +/- 3.1% for HTB.,"Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643505/),%,98.5,20536,DB08814,Triflusal
,18677970,Cmax,"Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[mg] / [l],16.85,52576,DB08814,Triflusal
,18677970,Cmax,"Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[mg] / [l],14.48,52577,DB08814,Triflusal
,18677970,AUC0-t,"Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[mg] / [h·l],18.43,52578,DB08814,Triflusal
,18677970,AUC0-t,"Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[mg] / [h·l],16.22,52579,DB08814,Triflusal
,18677970,Tmax,"Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),h,1,52580,DB08814,Triflusal
,18677970,Tmax,"Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),h,0.875,52581,DB08814,Triflusal
,18677970,t(1/2),"Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),,0.49,52582,DB08814,Triflusal
,18677970,t(1/2),"Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),,0.76,52583,DB08814,Triflusal
,18677970,Cmax,"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[mg] / [l],68.13,52584,DB08814,Triflusal
,18677970,Cmax,"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[mg] / [l],65.51,52585,DB08814,Triflusal
,18677970,AUC0-t,"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[h·mg] / [l],2748.18,52586,DB08814,Triflusal
,18677970,AUC0-t,"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[h·mg] / [l],2877.97,52587,DB08814,Triflusal
,18677970,AUC0-infinity,"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[h·mg] / [l],3350.15,52588,DB08814,Triflusal
,18677970,AUC0-infinity,"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),[h·mg] / [l],3372.49,52589,DB08814,Triflusal
,18677970,Tmax,"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),h,1-10,52590,DB08814,Triflusal
,18677970,t(1/2),"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),h,42.19,52591,DB08814,Triflusal
,18677970,t(1/2),"HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h).",Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677970/),h,43.13,52592,DB08814,Triflusal
,2272716,t1/2,Triflusal (t1/2 = 29-35 min) metabolized rapidly into HTB.,Pharmacokinetics of triflusal after single and repeated doses in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),min,29-35,87987,DB08814,Triflusal
,2272716,Cmax-ss,"After the administration of 300 mg every 8 h, the parameters obtained for HTB were: Cmax-ss = 178 +/- 42 micrograms/ml, tmax-ss = 1.9 +/- 0.7 h, Cmin-ss = 155.6 +/- 41.2 micrograms/ml, Cavg-ss = 168.0 +/- 41.8 micrograms/ml and a t1/2 of 48 +/- 15 h.",Pharmacokinetics of triflusal after single and repeated doses in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),[μg] / [ml],178,87988,DB08814,Triflusal
,2272716,tmax-ss,"After the administration of 300 mg every 8 h, the parameters obtained for HTB were: Cmax-ss = 178 +/- 42 micrograms/ml, tmax-ss = 1.9 +/- 0.7 h, Cmin-ss = 155.6 +/- 41.2 micrograms/ml, Cavg-ss = 168.0 +/- 41.8 micrograms/ml and a t1/2 of 48 +/- 15 h.",Pharmacokinetics of triflusal after single and repeated doses in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),h,1.9,87989,DB08814,Triflusal
,2272716,Cmin-ss,"After the administration of 300 mg every 8 h, the parameters obtained for HTB were: Cmax-ss = 178 +/- 42 micrograms/ml, tmax-ss = 1.9 +/- 0.7 h, Cmin-ss = 155.6 +/- 41.2 micrograms/ml, Cavg-ss = 168.0 +/- 41.8 micrograms/ml and a t1/2 of 48 +/- 15 h.",Pharmacokinetics of triflusal after single and repeated doses in man. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),[μg] / [ml],155.6,87990,DB08814,Triflusal
,2272716,Cavg-ss,"After the administration of 300 mg every 8 h, the parameters obtained for HTB were: Cmax-ss = 178 +/- 42 micrograms/ml, tmax-ss = 1.9 +/- 0.7 h, Cmin-ss = 155.6 +/- 41.2 micrograms/ml, Cavg-ss = 168.0 +/- 41.8 micrograms/ml and a t1/2 of 48 +/- 15 h.",Pharmacokinetics of triflusal after single and repeated doses in man. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),[μg] / [ml],168.0,87991,DB08814,Triflusal
,2272716,t1/2,"After the administration of 300 mg every 8 h, the parameters obtained for HTB were: Cmax-ss = 178 +/- 42 micrograms/ml, tmax-ss = 1.9 +/- 0.7 h, Cmin-ss = 155.6 +/- 41.2 micrograms/ml, Cavg-ss = 168.0 +/- 41.8 micrograms/ml and a t1/2 of 48 +/- 15 h.",Pharmacokinetics of triflusal after single and repeated doses in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),h,48,87992,DB08814,Triflusal
,2272716,Cmax-ss,"The parameters obtained for the dosage of 600 mg every 24 h were: Cmax-ss = 153 +/- 40 micrograms/ml, tmax-ss = 2.7 +/- 0.9 h, and a t1/2 of 50 +/- 16 h.",Pharmacokinetics of triflusal after single and repeated doses in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),[μg] / [ml],153,87993,DB08814,Triflusal
,2272716,tmax-ss,"The parameters obtained for the dosage of 600 mg every 24 h were: Cmax-ss = 153 +/- 40 micrograms/ml, tmax-ss = 2.7 +/- 0.9 h, and a t1/2 of 50 +/- 16 h.",Pharmacokinetics of triflusal after single and repeated doses in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),h,2.7,87994,DB08814,Triflusal
,2272716,t1/2,"The parameters obtained for the dosage of 600 mg every 24 h were: Cmax-ss = 153 +/- 40 micrograms/ml, tmax-ss = 2.7 +/- 0.9 h, and a t1/2 of 50 +/- 16 h.",Pharmacokinetics of triflusal after single and repeated doses in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2272716/),h,50,87995,DB08814,Triflusal
,25546165,Cmax,"The mean Cmax of triflusal and HTB were 13.96, 110.2 ug/mL for the fasting state and 9.546, 97.15 ug/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[ug] / [ml],13.96,95489,DB08814,Triflusal
,25546165,Cmax,"The mean Cmax of triflusal and HTB were 13.96, 110.2 ug/mL for the fasting state and 9.546, 97.15 ug/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[ug] / [ml],110.2,95490,DB08814,Triflusal
,25546165,Cmax,"The mean Cmax of triflusal and HTB were 13.96, 110.2 ug/mL for the fasting state and 9.546, 97.15 ug/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[ug] / [ml],9.546,95491,DB08814,Triflusal
,25546165,Cmax,"The mean Cmax of triflusal and HTB were 13.96, 110.2 ug/mL for the fasting state and 9.546, 97.15 ug/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[ug] / [ml],97.15,95492,DB08814,Triflusal
,25546165,AUC0-144,"The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxμg/mL for the fasting state and 22.20, 5,038 hxμg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxμg/mL for the fasting state and 22.44, 5,632 hxμg/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[h·μg] / [ml],19.66,95493,DB08814,Triflusal
,25546165,AUC0-144,"The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxμg/mL for the fasting state and 22.20, 5,038 hxμg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxμg/mL for the fasting state and 22.44, 5,632 hxμg/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[h·μg] / [ml],"5,572",95494,DB08814,Triflusal
,25546165,AUC0-144,"The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxμg/mL for the fasting state and 22.20, 5,038 hxμg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxμg/mL for the fasting state and 22.44, 5,632 hxμg/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[h·μg] / [ml],22.20,95495,DB08814,Triflusal
,25546165,AUC0-144,"The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxμg/mL for the fasting state and 22.20, 5,038 hxμg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxμg/mL for the fasting state and 22.44, 5,632 hxμg/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[h·μg] / [ml],"5,038",95496,DB08814,Triflusal
,25546165,AUC0-∞,"The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxμg/mL for the fasting state and 22.20, 5,038 hxμg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxμg/mL for the fasting state and 22.44, 5,632 hxμg/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[h·μg] / [ml],19.79,95497,DB08814,Triflusal
,25546165,AUC0-∞,"The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxμg/mL for the fasting state and 22.20, 5,038 hxμg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxμg/mL for the fasting state and 22.44, 5,632 hxμg/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[h·μg] / [ml],"6,333",95498,DB08814,Triflusal
,25546165,AUC0-∞,"The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxμg/mL for the fasting state and 22.20, 5,038 hxμg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxμg/mL for the fasting state and 22.44, 5,632 hxμg/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[h·μg] / [ml],22.44,95499,DB08814,Triflusal
,25546165,AUC0-∞,"The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxμg/mL for the fasting state and 22.20, 5,038 hxμg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxμg/mL for the fasting state and 22.44, 5,632 hxμg/mL for the fed state, respectively.","Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25546165/),[h·μg] / [ml],"5,632",95500,DB08814,Triflusal
,1823870,Cmax,Triflusal displays a Cmax of 11.6 +/- 1.7 micrograms/ml and a tmax of 0.88 +/- 0.26 h.,Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823870/),[μg] / [ml],11.6,106972,DB08814,Triflusal
,1823870,tmax,Triflusal displays a Cmax of 11.6 +/- 1.7 micrograms/ml and a tmax of 0.88 +/- 0.26 h.,Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823870/),h,0.88,106973,DB08814,Triflusal
,1823870,elimination half-life (t1/2),The elimination half-life (t1/2) was 0.55 h with a clearance (Cl/F) of 45.5 +/- 11.0 l/h.,Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823870/),h,0.55,106974,DB08814,Triflusal
,1823870,clearance (Cl/F),The elimination half-life (t1/2) was 0.55 h with a clearance (Cl/F) of 45.5 +/- 11.0 l/h.,Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823870/),[l] / [h],45.5,106975,DB08814,Triflusal
,1823870,tmax,"HTB kinetic parameters were: tmax 4.96 +/- 1.37 h and Cmax 92.7 +/- 17.1 micrograms/ml, with an elimination t1/2 of 34.3 +/- 5.3 and a clearance of 0.18 +/- 0.04 l/h.",Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823870/),h,4.96,106976,DB08814,Triflusal
,1823870,Cmax,"HTB kinetic parameters were: tmax 4.96 +/- 1.37 h and Cmax 92.7 +/- 17.1 micrograms/ml, with an elimination t1/2 of 34.3 +/- 5.3 and a clearance of 0.18 +/- 0.04 l/h.",Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823870/),[μg] / [ml],92.7,106977,DB08814,Triflusal
,1823870,elimination t1/2,"HTB kinetic parameters were: tmax 4.96 +/- 1.37 h and Cmax 92.7 +/- 17.1 micrograms/ml, with an elimination t1/2 of 34.3 +/- 5.3 and a clearance of 0.18 +/- 0.04 l/h.",Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823870/),,34.3,106978,DB08814,Triflusal
,1823870,clearance,"HTB kinetic parameters were: tmax 4.96 +/- 1.37 h and Cmax 92.7 +/- 17.1 micrograms/ml, with an elimination t1/2 of 34.3 +/- 5.3 and a clearance of 0.18 +/- 0.04 l/h.",Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823870/),[l] / [h],0.18,106979,DB08814,Triflusal
,11862303,t(max),"After a single administration, unchanged triflusal is promptly absorbed (t(max) 0.75 h, C(max) 3.83 &mgr;g/mL) and rapidly depleted from the systemic circulation.",Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862303/),h,0.75,138337,DB08814,Triflusal
,11862303,C(max),"After a single administration, unchanged triflusal is promptly absorbed (t(max) 0.75 h, C(max) 3.83 &mgr;g/mL) and rapidly depleted from the systemic circulation.",Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862303/),[&mgr;g] / [ml],3.83,138338,DB08814,Triflusal
,11862303,apparent terminal half-life,The apparent terminal half-life was 0.85 h.,Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862303/),h,0.85,138339,DB08814,Triflusal
,11862303,t(max),"HTB proves to be quickly generated from triflusal (t(max) 2.00 h, C(max) 39.88 &mgr;g/mL) and slowly eliminated from the body (t = 54.6 h).",Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862303/),h,2.00,138340,DB08814,Triflusal
,11862303,C(max),"HTB proves to be quickly generated from triflusal (t(max) 2.00 h, C(max) 39.88 &mgr;g/mL) and slowly eliminated from the body (t = 54.6 h).",Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862303/),[&mgr;g] / [ml],39.88,138341,DB08814,Triflusal
,11862303,t,"HTB proves to be quickly generated from triflusal (t(max) 2.00 h, C(max) 39.88 &mgr;g/mL) and slowly eliminated from the body (t = 54.6 h).",Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862303/),h,54.6,138342,DB08814,Triflusal
,11862303,steady-state levels,"Conversely, HTB plasma concentration builds up progressively toward steady-state levels of approximately 102 &mgr;g/mL after 4 to 5 d of treatment.",Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862303/),[&mgr;g] / [ml],102,138343,DB08814,Triflusal
,1823869,biological half-life (t1/2),"In rats, triflusal was quickly eliminated from plasma with a biological half-life (t1/2) of 2.7 min and a clearance (Cl) of 73.4 (ml/kg)/min.",Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),min,2.7,141998,DB08814,Triflusal
,1823869,clearance (Cl),"In rats, triflusal was quickly eliminated from plasma with a biological half-life (t1/2) of 2.7 min and a clearance (Cl) of 73.4 (ml/kg)/min.",Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),[ml] / [kg)·min],73.4,141999,DB08814,Triflusal
,1823869,t1/2,The elimination of HTB was much slower with a t1/2 of 21.5 h and a Cl of 5.1 (mg/kg)/h.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),h,21.5,142000,DB08814,Triflusal
,1823869,Cl,The elimination of HTB was much slower with a t1/2 of 21.5 h and a Cl of 5.1 (mg/kg)/h.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),[mg] / [h·kg)],5.1,142001,DB08814,Triflusal
,1823869,maximum concentration (Cmax),The maximum concentration (Cmax) of triflusal in rats after an oral administration was 8.1 +/- 2.0 micrograms/ml reached between 2.5 and 10 min.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),[μg] / [ml],8.1,142002,DB08814,Triflusal
,1823869,Cmax,The Cmax of HTB was 237.7 micrograms/ml and was achieved at 0.7 h.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),[μg] / [ml],237.7,142003,DB08814,Triflusal
,1823869,bioavailability,The bioavailability of triflusal in rats was only 10.6% while the bioavailability of HTB was more than 100% indicating an important first pass effect.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),%,10.6,142004,DB08814,Triflusal
more,1823869,bioavailability,The bioavailability of triflusal in rats was only 10.6% while the bioavailability of HTB was more than 100% indicating an important first pass effect.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),%,100,142005,DB08814,Triflusal
,1823869,t1/2,In dogs the t1/2 of triflusal was 14.4 +/- 5.9 min and the Cl was 25.1 +/- 4.7 (ml/kg)/min.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),min,14.4,142006,DB08814,Triflusal
,1823869,Cl,In dogs the t1/2 of triflusal was 14.4 +/- 5.9 min and the Cl was 25.1 +/- 4.7 (ml/kg)/min.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),[ml] / [kg)·min],25.1,142007,DB08814,Triflusal
,1823869,t1/2,HTB was also eliminated very slowly with a t1/2 of 71.1 +/- 12.5 h and a Cl of 2.4 +/- 0.3 (ml/kg)/h.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),h,71.1,142008,DB08814,Triflusal
,1823869,Cl,HTB was also eliminated very slowly with a t1/2 of 71.1 +/- 12.5 h and a Cl of 2.4 +/- 0.3 (ml/kg)/h.,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),[ml] / [h·kg)],2.4,142009,DB08814,Triflusal
,1823869,Cmax,The Cmax of triflusal in dogs was 13.3 +/- 2.9 micrograms/ml and was reached after 19.2 +/- 6.1 min (tmax).,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),[μg] / [ml],13.3,142010,DB08814,Triflusal
,1823869,tmax,The Cmax of triflusal in dogs was 13.3 +/- 2.9 micrograms/ml and was reached after 19.2 +/- 6.1 min (tmax).,Pharmacokinetics of triflusal and its main metabolite in rats and dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823869/),min,19.2,142011,DB08814,Triflusal
,15711832,concentrations,CSF concentrations of HTB ranged between 0.011 microg/ml and 0.341 microg/ml.,"Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15711832/),[μg] / [ml],0.011,198968,DB08814,Triflusal
,15711832,concentrations,CSF concentrations of HTB ranged between 0.011 microg/ml and 0.341 microg/ml.,"Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15711832/),[μg] / [ml],0.341,198969,DB08814,Triflusal
,15711832,CSF-plasma partition coefficient,A CSF-plasma partition coefficient of 0.002 and a k(e0) value of 0.059 h(-1) were estimated by means of population modeling.,"Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15711832/),,0.002,198970,DB08814,Triflusal
,15711832,k(e0),A CSF-plasma partition coefficient of 0.002 and a k(e0) value of 0.059 h(-1) were estimated by means of population modeling.,"Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15711832/),1/[h],0.059,198971,DB08814,Triflusal
,24105106,Tmax,"After single-dose administration, triflusal was rapidly absorbed with a mean Tmax of 0.55-0.92 h and a mean t1/2 kel of 0.35-0.65 h, HTB was absorbed with a mean Tmax of 2.35-3.03 h and a mean t1/2 kel of 52.5-65.57 h.","Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24105106/),h,0.55-0.92,256028,DB08814,Triflusal
,24105106,t1/2 kel,"After single-dose administration, triflusal was rapidly absorbed with a mean Tmax of 0.55-0.92 h and a mean t1/2 kel of 0.35-0.65 h, HTB was absorbed with a mean Tmax of 2.35-3.03 h and a mean t1/2 kel of 52.5-65.57 h.","Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24105106/),h,0.35-0.65,256029,DB08814,Triflusal
,24105106,Tmax,"After single-dose administration, triflusal was rapidly absorbed with a mean Tmax of 0.55-0.92 h and a mean t1/2 kel of 0.35-0.65 h, HTB was absorbed with a mean Tmax of 2.35-3.03 h and a mean t1/2 kel of 52.5-65.57 h.","Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24105106/),h,2.35-3.03,256030,DB08814,Triflusal
,24105106,t1/2 kel,"After single-dose administration, triflusal was rapidly absorbed with a mean Tmax of 0.55-0.92 h and a mean t1/2 kel of 0.35-0.65 h, HTB was absorbed with a mean Tmax of 2.35-3.03 h and a mean t1/2 kel of 52.5-65.57 h.","Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24105106/),h,52.5-65.57,256031,DB08814,Triflusal
,25534747,oral clearance (CL/F),"The structure and the population estimates for triflusal PK were as follows: oral clearance (CL/F) = 0.2 · (weight/71.65)(0.845) L/h, oral volume of distribution (V/F) = 8.3 · (weight/71.65) L, and k f = 0.341 h(-1).","Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25534747/),[l] / [h],0.2,271363,DB08814,Triflusal
,25534747,oral volume of distribution (V/F),"The structure and the population estimates for triflusal PK were as follows: oral clearance (CL/F) = 0.2 · (weight/71.65)(0.845) L/h, oral volume of distribution (V/F) = 8.3 · (weight/71.65) L, and k f = 0.341 h(-1).","Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25534747/),,8.3,271364,DB08814,Triflusal
,25534747,k f,"The structure and the population estimates for triflusal PK were as follows: oral clearance (CL/F) = 0.2 · (weight/71.65)(0.845) L/h, oral volume of distribution (V/F) = 8.3 · (weight/71.65) L, and k f = 0.341 h(-1).","Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25534747/),1/[h],0.341,271365,DB08814,Triflusal
,25534747,EC 50,The current dosing regimen was considered to be efficacious based on the EC 50 estimate of 84.9 μg/mL obtained in this study.,"Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25534747/),[μg] / [ml],84.9,271366,DB08814,Triflusal
